Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2004-12-06
2009-11-24
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S147100, C435S440000, C435S069600, C435S069700, C530S387300, C530S388300, C530S413000, C536S023400, C536S023530
Reexamination Certificate
active
07622112
ABSTRACT:
Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.
REFERENCES:
patent: 2005/027847 (2004-03-01), None
patent: 2004/092332 (2004-10-01), None
patent: 2004/092360 (2004-10-01), None
patent: 2005/010034 (2005-02-01), None
Gubbins MJ et al “Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus” Molecular Immunology vol. 42, Aug. 9, 2004 pp. 125-136.
Berry JD et al “Development and characterization of neutralising monoclonal antibody to the SARS-coronavirus” Journal of Virological Methods vol. 120 No. 1. Sep. 1, 2004 pp. 87-96.
Sui J. et al “Potent neutralization of Severe Acute Respiratory Syndrome (SARS) coronavirus by a human MAb to S1 protein that blocks receptor association” Proceedings of the National Academy of Sciences vol. 101, No. 8 Feb. 24, 2004 pp. 2536-2541.
Zhou et al “An exposed domain in the Severe Acute Respiratory Syndrome coronavirus spike protein induces neutralizing antibodies” Journal of Virology vol. 78 No. 13 Jul. 2004 pp. 7217-7226.
Che Xy et al “Rapid and efficient preparation of monoclonal antibodies against SARS associated coronavirus nucleocapsid protein by immunizing mice” Di YiJun Yi Da Xue Xue Bao vol. 23 No. 7 Jul. 2003 pp. 640-642.
He Y et al “Receptor binding domain of SARS CoV spike protein induces highly potent neutralizing antibodies: implicated for developing subunit vaccine” Biochemical and Biophysical Research Communications vol. 324, Oct. 2, 2004 pp. 773-781.
Xiong S et al “immunogenicity of SARS inactivated vaccine in BALB/c mice ” Immunology Letters vol. 95, Aug. 1, 2004 pp. 139-143.
Holmes K: :SARS coronavirus: a new challenge for prevention and therapy: The Journal of Clinicla Investigation vol. 111, Jun. 1, 2003 pp. 1605-1609.
Rota PA et al “Characterization of a novel coronavirus associat ed with severe acute respiratory syndrome ”Science vol. 300 May 30, 2003 pp. 1394-1399.
Andonov Anton
Berry Jody
Drebot Mike
Gubbins Mike
Jones Steven
Ade & Company Inc.
Mosher Mary E
Williams Michael R.
LandOfFree
Anti-SARS monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-SARS monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-SARS monoclonal antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068391